Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
MDC-Verte Fund is a joint initiative established in 2021 between MDC-Studio and the Verte Opportunity Zone Fund, aimed at providing capital for early-stage companies, particularly in the medical technology sector. Based in Baltimore, Maryland, the fund focuses on supporting innovators, inventors, and entrepreneurs located in Opportunity Zones across the United States. This strategic focus allows the fund to leverage a strong clinical and academic network to enhance the growth potential of its portfolio companies.
The fund operates as a Qualified Opportunity Fund, offering tax incentives to investors, including capital gains tax deferral and potential avoidance. This structure not only attracts investment but also aligns with the fund's mission to support early-stage medical technology ventures. The fund's unique positioning within the Baltimore medtech ecosystem, combined with its partnerships with clinical operators and academic institutions, positions it as a significant player in the early-stage investment landscape.
MDC-Verte Fund primarily invests in early-stage medical technology companies, specifically targeting those located in Opportunity Zones. The fund's investment strategy encompasses several key areas, including medical devices for surgery and trauma care, wearable technologies for diagnostics and health monitoring, and robotic technologies for rehabilitation and surgery. The fund aims to bridge the gap between initial funding from personal networks and traditional later-stage investments, facilitating a smoother transition for startups seeking to scale.
Investment sizes typically range from $100,000 to $5 million, covering pre-seed, seed, and Series A stages. The fund emphasizes the importance of innovative solutions that address critical healthcare challenges, particularly in underserved areas. MDC-Verte Fund also provides non-dilutive government funding support as part of its investment model, enhancing the financial resources available to its portfolio companies.
MDC-Verte Fund's portfolio includes 13 companies, showcasing a diverse range of medical technology innovations. Notable portfolio companies include:
In addition to these, there are five other unnamed portfolio companies that contribute to the fund's diverse investment strategy. The fund's focus on medical technology, particularly in Opportunity Zones, underscores its commitment to addressing healthcare challenges through innovation.
Aldo Iacono, MD - Partner: Dr. Iacono brings extensive experience in the medical field, having co-founded Aerea Medical. His expertise lies in medical technology and innovation, particularly in respiratory disease management.
Dianna Lesage - Team Member: Dianna is an integral part of the MDC-Verte Fund team, contributing to the fund's operations and support for portfolio companies. Her background includes experience in venture capital and startup ecosystems.
To pitch MDC-Verte Fund, founders should submit their proposals through the fund's website at mdc-verte.com. The pitch deck should include a comprehensive overview of the business model, market analysis, and details about the founding team. It is recommended to highlight any traction or early successes.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, especially from individuals within the fund's network, which can enhance the chances of securing a meeting.
As of 2023, MDC-Verte Fund has been actively promoting its mission to support innovators and entrepreneurs in the medical technology sector, particularly in Opportunity Zones. The fund has recently highlighted its focus areas and notable portfolio companies on its website. Notable activity includes the graduation of Next Step Robotics in 2021, which completed human trials and is currently preparing for FDA clearance.
The fund is also accepting new company submissions and remains active in deal flow, indicating a commitment to expanding its portfolio and supporting emerging medical technology ventures.
What are the investment criteria for MDC-Verte Fund?
MDC-Verte Fund primarily invests in early-stage medical technology companies located in Opportunity Zones. The fund focuses on sectors such as medical devices for surgery and trauma care, wearable technologies for diagnostics and health monitoring, and robotic technologies for rehabilitation and surgery.
How can I apply or pitch to MDC-Verte Fund?
Founders can submit their pitches through the fund's website at mdc-verte.com. It is advisable to include a detailed business plan, market analysis, and information about the founding team in the pitch deck.
What makes MDC-Verte Fund different from other venture capital firms?
MDC-Verte Fund is unique in its focus on Opportunity Zones and its strong clinical and academic network in the Baltimore area. This allows the fund to provide not only capital but also valuable resources and connections to its portfolio companies.
What is the geographic scope of MDC-Verte Fund's investments?
The fund primarily targets investments in Opportunity Zones across the United States, with a particular emphasis on Maryland. However, it is open to opportunities nationwide.
What is the typical fund size and check size for investments?
The fund size is not publicly disclosed, but investment sizes typically range from $100,000 to $5 million, covering pre-seed, seed, and Series A stages.
What kind of post-investment involvement does MDC-Verte Fund have?
MDC-Verte Fund provides ongoing support to its portfolio companies, including access to a robust network of clinical operators and academic resources. The fund also assists in navigating the funding landscape, including access to non-dilutive government funding.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.